Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch Health Companies Inc.

https://www.bauschhealth.com/

Latest From Bausch Health Companies Inc.

Since 2012, No Shortage Of Variety In US OTC Switches While Short Of Chronic Conditions

From intranasal corticosteroids to a lice treatment, and from an addition to the OTC PPI market to the first nonprescription acne drug reaching the market through an NDA, US OTC switches in the past 10 years, since FDA began considering widening switch opportunities, haven’t lacked for variety.

FDA Prescription To OTC Switch

Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market

Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.

Financing Business Strategies

Physician Communication That Combined Results Of Unrelated Studies Gets Rebuke From US FDA

Althera’s misleading claims about its cholesterol drug Roszet is based on a ‘scientifically unsound analysis,’ OPDP tells company. FDA says studies cited in the pamphlet for doctors do not support claims regarding the magnitude of treatment effect.

Advertising, Marketing & Sales Metabolic Disorders

Bausch + Lomb’s First Results Look Familiar

January-March results Bausch + Lomb reported on 8 June were included in Bausch Health’s results published in May on the same day it closed an IPO shares to separate its eye health and vision care business. Guidance it provided, however, was new and a first for Bausch + Lomb.

Sales & Earnings M & A
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • AB Sanitas
    • Afexa Life Sciences Inc.
    • Amoun Pharmaceutical
    • Aton Pharma, Inc.
    • Bausch Health Ireland Limited
    • Bausch + Lomb Holding International
    • Biovail Corporation
    • Callisto Pharmaceuticals, Inc. Dendreon Corporation
    • Dermik Laboratories, Inc.
    • Dow Pharmaceutical Sciences, Inc.
    • Eyetech Inc.
    • Graceway Pharmaceuticals, LLC
    • ICN Pharmaceuticals, Inc.
    • iNova Diagnostics, Inc.
    • Instituto Terapeutico Delta Ltda
    • Medicis Aesthetics Holdings Inc
    • Medicis Pharmaceutical Corporation
    • Mercury (Cayman) Holdings
    • OraPharma, Inc.
    • Ortho Dermatologics
    • Prestwick Pharmaceuticals, Inc.
    • PharmaSwiss S.A.
    • Pedinol Pharmacal, Inc.
    • Salix Pharmaceuticals Ltd. (InKine Pharmaceutical
    • Oceana Therapeutics, LLC
    • Q-Med Scandinavia, Inc.
    • Santarus, Inc.)
    • Sanitas AB
    • Solta Medical, Inc.
    • SPI Pharmaceuticals Inc
    • Synergetics USA, Inc.
    • Synergy Pharmaceuticals Inc.(SGYP)
    • Technolas Perfect Vision GmbH (TPV)
    • Ucyclyd Pharma, Inc.
    • Unilens Vision, Inc.
    • Viratek Pharma Inc
    • Valeant Pharmaceuticals International, Inc.
    • Xcel Pharmaceuticals, Inc.
UsernamePublicRestriction

Register